ARTICLE | Clinical News
Ontak denileukin diftitox: Began Phase II trial
January 22, 2001 8:00 AM UTC
Ligand Pharmaceuticals Inc. (LGND), San Diego, Calif. Product: Ontak denileukin diftitox ( DAB389IL2) Business: Cancer Therapeutic category: Cytotoxic Target: CD25 component of IL-2 receptor Descrip...